Sibylle Loibl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/712130/publications.pdf

Version: 2024-02-01

271	45,952	5248	2071
papers	citations	83 h-index	204 g-index

275	275	275	35170
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, The, 2014, 384, 164-172.	6.3	3,224
2	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, 2013, 24, 2206-2223.	0.6	2,805
3	Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. Journal of Clinical Oncology, 2012, 30, 1796-1804.	0.8	2,062
4	Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. New England Journal of Medicine, 2019, 380, 617-628.	13.9	1,610
5	Alpelisib for PIK3CA-Mutated, Hormone Receptorâ€“Positive Advanced Breast Cancer. New England Journal of Medicine, 2019, 380, 1929-1940.	13.9	1,582
6	Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer. Journal of Clinical Oncology, 2010, 28, 105-113.	0.8	1,438
7	Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncology, The, 2018, 19, 40-50.	5.1	1,327
8	Palbociclib in Hormone-Receptorâ€“Positive Advanced Breast Cancer. New England Journal of Medicine, 2015, 373, 209-219.	13.9	1,239
9	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	13.7	1,099
10	Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2â€“Positive and Triple-Negative Primary Breast Cancers. Journal of Clinical Oncology, 2015, 33, 983-991.	0.8	863
11	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncology, The, 2014, 15, 747-756.	5.1	810
12	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. New England Journal of Medicine, 2018, 379, 1926-1936.	13.9	805
13	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 2020, 382, 597-609.	13.9	789
14	Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. New England Journal of Medicine, 2021, 384, 2394-2405.	13.9	764
15	Breast cancer. Lancet, The, 2021, 397, 1750-1769.	6.3	731
16	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncology, The, 2018, 19, 27-39.	5.1	717
17	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	2.6	711
18	Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2â€“Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study. Journal of Clinical Oncology, 2009, 27, 1999-2006.	0.8	685

#	Article	IF	Citations
19	HER2-positive breast cancer. Lancet, The, 2017, 389, 2415-2429.	6.3	655
20	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 2021, 384, 1529-1541.	13.9	601
21	Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer. Clinical Cancer Research, 2009, 15, 1452-1459.	3.2	592
22	Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update. Journal of Clinical Oncology, 2006, 24, 1940-1949.	0.8	579
23	Plasma ESR1 Mutations and the Treatment of Estrogen Receptorâ€“Positive Advanced Breast Cancer. Journal of Clinical Oncology, 2016, 34, 2961-2968.	0.8	573
24	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Nonâ€“Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 2017, 24, 311-335.	2.4	530
25	Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 497-509.	5.1	530
26	Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncology, The, 2012, 13, e148-e160.	5.1	505
27	Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study. Journal of Clinical Oncology, 2010, 28, 2024-2031.	0.8	487
28	Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer. New England Journal of Medicine, 2012, 366, 299-309.	13.9	473
29	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 2017, 24, 235-251.	2.4	469
30	Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial. Clinical Cancer Research, 2010, 16, 2634-2645.	3.2	463
31	Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2â€“Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups. Journal of Clinical Oncology, 2011, 29, 3351-3357.	0.8	456
32	Novel Theranostic Opportunities Offered by Characterization of Altered Membrane Lipid Metabolism in Breast Cancer Progression. Cancer Research, 2011, 71, 3236-3245.	0.4	444
33	Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncology, The, 2012, 13, 135-144.	5.1	425
34	The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. Cancer Discovery, 2018, 8, 1390-1403.	7.7	397
35	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 1485-1505.	0.8	395
36	Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Annals of Surgical Oncology, 2006, 13, 1702-1710.	0.7	367

#	Article	IF	Citations
37	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of Oncology, 2021, 32, 1216-1235.	0.6	354
38	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. Journal of Clinical Oncology, 2020, 38, 2610-2619.	0.8	331
39	Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSeptoâ€"GBG 69): a randomised, phase 3 trial. Lancet Oncology, The, 2016, 17, 345-356.	5.1	316
40	Response-Guided Neoadjuvant Chemotherapy for Breast Cancer. Journal of Clinical Oncology, 2013, 31, 3623-3630.	0.8	302
41	Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer. JAMA Oncology, 2017, 3, 1378.	3.4	300
42	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
43	Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial. Journal of the National Cancer Institute, 2008, 100, 542-551.	3.0	268
44	Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patientâ€"Level Data. Journal of Clinical Oncology, 2018, 36, 1981-1990.	0.8	268
45	Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptorâ€"Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2019, 37, 1169-1178.	0.8	266
46	Effect of Luteinizing Hormoneâ€"Releasing Hormone Agonist on Ovarian Function After Modern Adjuvant Breast Cancer Chemotherapy: The GBG 37 ZORO Study. Journal of Clinical Oncology, 2011, 29, 2334-2341.	0.8	263
47	Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy: Results From an International Collaborative Study. Journal of Clinical Oncology, 2013, 31, 2532-2539.	0.8	261
48	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37â€ˆ298 women with early breast cancer in 26 randomised trials. Lancet, The, 2019, 393, 1440-1452.	6.3	260
49	Effect of neoadjuvant anthracyclineâ€"taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Research and Treatment, 2010, 124, 133-140.	1.1	252
50	Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncology, The, 2021, 22, 1151-1161.	5.1	248
51	Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study. Journal of the National Cancer Institute, 2008, 100, 552-562.	3.0	231
52	PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Antiâ€"Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer. Journal of Clinical Oncology, 2014, 32, 3212-3220.	0.8	231
53	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology, 2016, 29, 1155-1164.	2.9	230
54	Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Research and Treatment, 2011, 125, 145-156.	1.1	228

#	Article	IF	Citations
55	Treatment of breast cancer during pregnancy: an observational study. Lancet Oncology, The, 2012, 13, 887-896.	5.1	224
56	Breast cancer in pregnancy. Lancet, The, 2012, 379, 570-579.	6.3	216
57	Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study. Journal of Clinical Oncology, 2010, 28, 2015-2023.	0.8	194
58	Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer â€“ A Substudy of the Neoadjuvant GeparQuinto Trial. PLoS ONE, 2013, 8, e79775.	1.1	187
59	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	9.4	184
60	Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2011, 130, 477-487.	1.1	180
61	Breast Cancer Diagnosed During Pregnancy. JAMA Oncology, 2015, 1, 1145.	3.4	169
62	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncology, The, 2021, 22, 212-222.	5.1	169
63	Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. Lancet, The, 2017, 389, 2403-2414.	6.3	168
64	Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 5747-5754.	3.2	158
65	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancerâ€”The Penelope-B Trial. Journal of Clinical Oncology, 2021, 39, 1518-1530.	0.8	153
66	Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene, 2002, 21, 3162-3171.	2.6	150
67	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13â€˜864 women in seven randomised trials. Lancet Oncology, The, 2021, 22, 1139-1150.	5.1	147
68	Second international consensus guidelines for breast cancer in young women (BCY2). Breast, 2016, 26, 87-99.	0.9	142
69	Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer. Clinical Cancer Research, 2013, 19, 4521-4531.	3.2	137
70	First international consensus guidelines for breast cancer in young women (BCY1). Breast, 2014, 23, 209-220.	0.9	135
71	Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. Journal of Clinical Oncology, 2019, 37, 2257-2269.	0.8	135
72	Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet, The, 2020, 395, 117-122.	6.3	128

#	Article	IF	Citations
73	Silencing of the HER2/neu Gene by siRNA Inhibits Proliferation and Induces Apoptosis in HER2/neu-Overexpressing Breast Cancer Cells. Neoplasia, 2004, 6, 786-795.	2.3	113
74	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2021, 7, 150.	2.3	112
75	Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Research and Treatment, 2014, 147, 61-68.	1.1	108
76	Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. Oncologist, 2017, 22, 1028-1038.	1.9	108
77	13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus - Opinion of a German Team of Experts (Zurich 2013). Breast Care, 2013, 8, 221-229.	0.8	98
78	NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69â€“GeparSepto. Journal of Clinical Oncology, 2019, 37, 2226-2234.	0.8	95
79	Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Research and Treatment, 2014, 144, 153-162.	1.1	92
80	Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Research and Treatment, 2015, 150, 127-139.	1.1	92
81	Classical pathology and mutational load of breast cancer â€“ integration of two worlds. Journal of Pathology: Clinical Research, 2015, 1, 225-238.	1.3	91
82	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 127-138.	5.1	91
83	Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. BMC Cancer, 2011, 11, 131.	1.1	87
84	BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. Journal of Clinical Oncology, 2018, 36, 2281-2287.	0.8	86
85	Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Breast Cancer Research and Treatment, 2015, 152, 377-387.	1.1	85
86	Standardized Ki67 Diagnostics Using Automated Scoringâ€”Clinical Validation in the GeparTrio Breast Cancer Study. Clinical Cancer Research, 2015, 21, 3651-3657.	3.2	85
87	Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. Clinical Cancer Research, 2017, 23, 5384-5393.	3.2	85
88	Intense dose-dense epirubicin, paclitaxel, cyclophosphamideÂversus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOctoâ€”GBG 84): A randomised phase III trial. European Journal of Cancer, 2019, 106, 181-192.	1.3	84
89	Surgical Procedures After Neoadjuvant Chemotherapy in Operable Breast Cancer: Results of the GEPARDUO Trial. Annals of Surgical Oncology, 2006, 13, 1434-1442.	0.7	83
90	Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. British Journal of Cancer, 2015, 113, 1565-1570.	2.9	83

#	Article	IF	Citations
91	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806.	0.9	81
92	Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. JAMA Surgery, 2020, 155, e195410.	2.2	81
93	Cytoplasmic Poly(Adenosine Diphosphateâ€“Ribose) Polymerase Expression Is Predictive and Prognostic in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy. Journal of Clinical Oncology, 2011, 29, 2150-2157.	0.8	79
94	Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer. JAMA - Journal of the American Medical Association, 2016, 316, 1888.	3.8	79
95	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discovery, 2021, 11, 2796-2811.	7.7	79
96	Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2015, 22, 1118-1127.	0.7	77
97	Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)Â±bevacizumab â€“ Results of the randomised GeparQuinto study (GBG 44). European Journal of Cancer, 2013, 49, 2284-2293.	1.3	75
98	The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. Breast, 2018, 42, 41-49.	0.9	75
99	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care, 2019, 14, 224-245.	0.8	72
100	Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. Cell Death and Differentiation, 2021, 28, 2778-2796.	5.0	72
101	Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy. Cancer, 2002, 95, 1191-1198.	2.0	70
102	Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) â€“ Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1056-1088.	0.8	69
103	NO Signaling Confers Cytoprotectivity through the Survivin Network in Ovarian Carcinomas. Cancer Research, 2008, 68, 5159-5166.	0.4	68
104	Integration of Metabolomics and Expression of Glycerol-3-phosphate Acyltransferase (GPAM) in Breast Cancerâ€”Link to Patient Survival, Hormone Receptor Status, and Metabolic Profiling. Journal of Proteome Research, 2012, 11, 850-860.	1.8	68
105	Poor Outcome in Estrogen Receptor-Positive Breast Cancers Predicted by Loss of Plexin B1. Clinical Cancer Research, 2007, 13, 1115-1122.	3.2	66
106	Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2â^’ ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. Clinical Cancer Research, 2022, 28, 3433-3442.	3.2	65
107	Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. Cancer Treatment Reviews, 2018, 67, 71-77.	3.4	64
108	Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). Breast Cancer Research and Treatment, 2012, 133, 387-391.	1.1	61

#	Article	IF	Citations
109	Neoadjuvant Chemotherapy Shows Similar Response in Patients With Inflammatory or Locally Advanced Breast Cancer When Compared With Operable Breast Cancer: A Secondary Analysis of the GeparTrio Trial Data. Journal of Clinical Oncology, 2010, 28, 83-91.	0.8	59
110	RANK expression as a prognostic and predictive marker in breast cancer. Breast Cancer Research and Treatment, 2014, 145, 307-315.	1.1	59
111	Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. Oncotarget, 2014, 5, 9952-9965.	0.8	58
112	Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy â€“ Results from the multi-center SENTINA trial. Breast, 2017, 31, 202-207.	0.9	57
113	The definition of pregnancy-associated breast cancer is outdated and should no longer be used. Lancet Oncology, The, 2021, 22, 753-754.	5.1	57
114	Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. Clinical Chemistry, 2019, 65, 1405-1413.	1.5	53
115	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	2.9	52
116	Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force. Cancer Treatment Reviews, 2016, 43, 19-26.	3.4	51
117	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast Care, 2021, 16, 214-227.	0.8	51
118	Role ofTP53mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. Oncotarget, 2016, 7, 67686-67698.	0.8	50
119	Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancerâ€”results from the GeparQuattro study (GBG 40). Breast Cancer Research and Treatment, 2012, 132, 863-870.	1.1	49
120	Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. Lancet Oncology, The, 2021, 22, e18-e28.	5.1	49
121	Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Research and Treatment, 2010, 123, 437-445.	1.1	47
122	A randomized phase 2 study comparing EC or CMF versus nabâ€paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to highâ€risk early breast cancer (ICE IIâ€GBG) Tj ETQq0 0 0 rgBT /Overlock 10	2.0	47
123	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. Breast Care, 2020, 15, 294-309.	0.8	47
124	Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer, 2016, 53, 65-74.	1.3	46
125	14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care, 2015, 10, 211-219.	0.8	43
126	Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance. Clinical Cancer Research, 2016, 22, 5238-5248.	3.2	43

#	Article	IF	Citations
127	Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). Journal of Clinical Oncology, 2018, 36, 1308-1316.	0.8	43
128	Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer. JAMA Oncology, 2020, 6, 744.	3.4	42
129	Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 2675-2683.	3.2	41
130	Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors â€“ An analysis of 2765 patients from neoadjuvant clinical trials. European Journal of Cancer, 2021, 148, 159-170.	1.3	41
131	Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients. International Journal of Cancer, 2014, 134, 1725-1733.	2.3	40
132	Lucitanib for the Treatment of HR+/HER2â˜’ Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. Clinical Cancer Research, 2020, 26, 354-363.	3.2	40
133	Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxaneâ€“Anthracycline Containing Chemotherapyâ€”DAFNE (GBG-70). Clinical Cancer Research, 2015, 21, 2924-2931.	3.2	38
134	Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. British Journal of Cancer, 2020, 123, 694-697.	2.9	37
135	Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. JAMA Oncology, 2021, 7, 603.	3.4	37
136	Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.. Journal of Clinical Oncology, 2019, 37, 1012-1012.	0.8	35
137	Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anti-Cancer Drugs, 2009, 20, 616-24.	0.7	34
138	Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer. Breast Care, 2016, 11, 96-100.	0.8	33
139	Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Research and Treatment, 2018, 167, 59-71.	1.1	32
140	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. Breast Care, 2019, 14, 247-255.	0.8	32
141	Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. Clinical Cancer Research, 2019, 25, 3986-3995.	3.2	32
142	Bevacizumab Treatment for Advanced Breast Cancer. Oncologist, 2011, 16, 1684-1697.	1.9	31
143	Genetic variants in <scp>VEGF</scp> pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III <scp>G</scp>epar<scp>Q</scp>uinto study. International Journal of Cancer, 2015, 137, 2981-2988.	2.3	31
144	Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Oncotarget, 2018, 9, 15168-15179.	0.8	29

#	Article	IF	Citations
145	Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. Annals of Surgical Oncology, 2019, 26, 3892-3901.	0.7	29
146	Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. Reproductive BioMedicine Online, 2019, 38, 835-844.	1.1	29
147	PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxaneâ€"Based Neoadjuvant Chemotherapy. Cancer Research and Treatment, 2020, 52, 689-696.	1.3	29
148	Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. Journal of Cancer Research and Clinical Oncology, 2013, 139, 2047-2056.	1.2	28
149	Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) â€" Recommendations for Daily Routine Practice. Geburtshilfe Und Frauenheilkunde, 2019, 79, 605-617.	0.8	28
150	Side Effects of Standard Adjuvant and Neoadjuvant Chemotherapy Regimens According to Age Groups in Primary Breast Cancer. Breast Care, 2013, 8, 60-66.	0.8	27
151	Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis. British Journal of Cancer, 2019, 120, 301-305.	2.9	27
152	Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer. Clinical Cancer Research, 2021, 27, 2584-2591.	3.2	27
153	Clinical relevance and concordance of HER2 status in local and central testingâ€"an analysis of 1581 HER2-positive breast carcinomas over 12 years. Modern Pathology, 2018, 31, 607-615.	2.9	25
154	Breast cancer, placenta and pregnancy. European Journal of Cancer, 2019, 115, 68-78.	1.3	24
155	Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men. JAMA Oncology, 2021, 7, 565.	3.4	24
156	Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer. JAMA Oncology, 2021, 7, 1291.	3.4	24
157	Comparison of pegfilgrastim on dayÂ2 vs. dayÂ4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Supportive Care in Cancer, 2011, 19, 1789-1795.	1.0	23
158	Surgical Outcome after Neoadjuvant Chemotherapy and Bevacizumab: Results from the GeparQuinto Study (GBG 44). Annals of Surgical Oncology, 2014, 21, 2517-2524.	0.7	23
159	Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOctoâ€GBG 84 Trial. Journal of the American Heart Association, 2020, 9, e018143.	1.6	23
160	Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptorâ€"Positive, Human Epidermal Growth Factor Receptor 2â€"Negative Advanced Breast Cancer From SOLAR-1. Journal of Clinical Oncology, 2021, 39, 2005-2015.	0.8	23
161	Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment. Oncotarget, 2016, 7, 13236-13247.	0.8	23
162	New Therapeutic Options for Breast Cancer during Pregnancy. Breast Care, 2008, 3, 4-4.	0.8	22

#	Article	IF	Citations
163	Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Research and Treatment, 2013, 139, 779-787.	1.1	21
164	Tumor-infiltrating lymphocytes in breast cancer. OncoImmunology, 2014, 3, e27926.	2.1	21
165	Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Breast Cancer Research, 2019, 21, 142.	2.2	21
166	Efficacy and safety of nab-paclitaxel 125Âmg/m2 and nab-paclitaxel 150Âmg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69). Breast Cancer Research and Treatment, 2017, 163, 495-506.	1.1	20
167	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. Breast Care, 2021, 16, 228-235.	0.8	20
168	Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer. International Journal of Cancer, 2002, 101, 390-394.	2.3	19
169	Update on neoadjuvant/preoperative therapy of breast cancer. Current Opinion in Obstetrics and Gynecology, 2013, 25, 66-73.	0.9	19
170	Predictive Factors for Response to Neoadjuvant Therapy in Breast Cancer. Oncology Research and Treatment, 2014, 37, 5-5.	0.8	19
171	Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer. Breast Cancer Research and Treatment, 2015, 149, 141-149.	1.1	19
172	Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature. Oncologist, 2018, 23, 974-981.	1.9	19
173	Optimal Systemic Treatment for Early Triple-Negative Breast Cancer. Breast Care, 2020, 15, 217-226.	0.8	19
174	AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. Geburtshilfe Und Frauenheilkunde, 2021, 81, 1112-1120.	0.8	17
175	Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial. Journal of Clinical Oncology, 2019, 37, 1490-1498.	0.8	16
176	Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 2587-2597.	3.2	16
177	Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy. Breast Care, 2011, 6, 279-283.	0.8	14
178	Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. Critical Reviews in Oncology/Hematology, 2012, 81, 136-150.	2.0	14
179	The Importance of Supportive Care in Breast Cancer Patients. Breast Care, 2014, 9, 230-231.	0.8	14
180	Neoadjuvant treatment of breast cancer. Current Opinion in Obstetrics and Gynecology, 2015, 27, 85-91.	0.9	14

#	Article	IF	Citations
181	Efficacy and safety of tailored and doseâ€dense adjuvant chemotherapy and trastuzumab for resected HER2â€positive breast cancer: Results from the phase 3 PANTHER trial. Cancer, 2020, 126, 1175-1182.	2.0	14
182	Patientâ€reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2â€“positive breast cancer. Cancer, 2020, 126, 3132-3139.	2.0	14
183	Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials. European Journal of Cancer, 2021, 152, 193-203.	1.3	14
184	Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. Oncotarget, 2015, 6, 30306-30316.	0.8	14
185	Use of goserelin in the treatment of breast cancer. Expert Review of Anticancer Therapy, 2005, 5, 591-604.	1.1	13
186	nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study. Expert Opinion on Drug Safety, 2010, 9, 515-523.	1.0	13
187	Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1681-1689.	1.2	13
188	Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). European Journal of Cancer, 2017, 84, 1-8.	1.3	13
189	Reactive stroma and trastuzumab resistance in HER2â€positive early breast cancer. International Journal of Cancer, 2020, 147, 266-276.	2.3	13
190	Effects of capecitabine as part of neo-/adjuvant chemotherapy â€“ A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. European Journal of Cancer, 2022, 166, 185-201.	1.3	13
191	Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls. European Journal of Cancer, 2022, 170, 54-63.	1.3	13
192	Oxaliplatin and 5-fluorouracil for heavily pretreated metastatic breast cancer: a preliminary phase II study. Anti-Cancer Drugs, 2003, 14, 549-553.	0.7	12
193	Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts. Breast Care, 2011, 6, 265-272.	0.8	12
194	Adverse Event Management of Oral Mucositis in Patients with Breast Cancer. Breast Care, 2014, 9, 232-237.	0.8	12
195	Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. International Journal of Cancer, 2019, 145, 857-868.	2.3	12
196	Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial. British Journal of Cancer, 2019, 121, 1009-1015.	2.9	12
197	Gene Expressionâ€“Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial. Clinical Cancer Research, 2021, 27, 2148-2158.	3.2	12
198	Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. European Journal of Cancer, 2022, 160, 100-111.	1.3	12

#	Article	IF	Citations
199	Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. European Journal of Cancer, 2022, 166, 219-228.	1.3	12
200	Being Pregnant and Diagnosed with Breast Cancer. Breast Care, 2012, 7, 204-209.	0.8	11
201	Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. Clinical Cancer Research, 2018, 24, 3358-3365.	3.2	11
202	Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer. Clinical Breast Cancer, 2016, 16, 444-455.	1.1	10
203	Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIIIâ€‰+â€‰IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. Breast Cancer Research and Treatment, 2019, 176, 557-568.	1.1	10
204	Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. Acta OncolÃ³gica, 2020, 59, 75-81.	0.8	10
205	Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.. Journal of Clinical Oncology, 2021, 39, TPS602-TPS602.	0.8	10
206	Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer. Breast, 2022, 62, S70-S79.	0.9	10
207	Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades. Archives of Gynecology and Obstetrics, 2013, 288, 1203-1212.	0.8	9
208	Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA*. Breast Care, 2014, 9, 169-174.	0.8	9
209	Neoadjuvant chemotherapy for early breast cancer. Lancet Oncology, The, 2018, 19, e129.	5.1	9
210	A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. Clinical Cancer Research, 2020, 26, 1896-1904.	3.2	9
211	A plain language summary of the ASCENTÂstudy: Sacituzumab Govitecan for metastatic triple-negative breast cancer. Future Oncology, 2021, 17, 3911-3924.	1.1	9
212	Bendamustine in Metastatic Breast Cancer: An Old Drug in New Design. Breast Care, 2008, 3, 333-339.	0.8	8
213	Model-based optimization of G-CSF treatment during cytotoxic chemotherapy. Journal of Cancer Research and Clinical Oncology, 2018, 144, 343-358.	1.2	8
214	MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial. PLoS ONE, 2020, 15, e0238021.	1.1	8
215	HER2-low-positive breast cancer from four neoadjuvant clinical trials â€“ Authors' reply. Lancet Oncology, The, 2021, 22, e427.	5.1	8
216	Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 47-59.	1.8	8

#	Article	IF	Citations
217	pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy â€“ A retrospective pooled analysis of individual patients data of four German neoadjuvant trials. Breast, 2017, 32, 73-78.	0.9	7
218	The rise of oncology biosimilars: from process to promise. Future Oncology, 2019, 15, 3255-3265.	1.1	7
219	CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality. Lancet Oncology, The, 2020, 21, 191-192.	5.1	7
220	Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome. European Journal of Cancer, 2021, 155, 13-24.	1.3	7
221	The GISS Trial: a Phase II Prevention Trial of Screening Plus Goserelin, Ibandronate, versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2141-2149.	1.1	6
222	A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. Breast Cancer Research and Treatment, 2021, 189, 15-23.	1.1	6
223	AGO Algorithms for the Treatment of Breast Cancer: Update 2021. Geburtshilfe Und Frauenheilkunde, 2021, 81, 1101-1111.	0.8	6
224	mdm2 gene amplification is associated with luminal breast cancer progression in humanized <scp>PDX</scp> mice and a worse outcome of estrogen receptor positive disease. International Journal of Cancer, 2022, 150, 1357-1372.	2.3	6
225	Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial. Cancer Chemotherapy and Pharmacology, 2009, 63, 953-958.	1.1	5
226	Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial. European Journal of Surgical Oncology, 2020, 46, 223-228.	0.5	5
227	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptorâ€“positive Early Breast Cancer: Results from the SOLE Trial. Clinical Cancer Research, 2021, 27, 504-512.	3.2	5
228	Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus. Geburtshilfe Und Frauenheilkunde, 2021, 81, 637-653.	0.8	5
229	Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.. Journal of Clinical Oncology, 2019, 37, 510-510.	0.8	5
230	EGF-R and Her2/neu overexpressing tumors: independent collectives for treatment of breast cancer by specific monoclonal antibody-therapy. Journal of Cancer Research and Clinical Oncology, 2003, 129, 250-251.	1.2	4
231	Darbepoetin Alfa as Primary Prophylaxis of Anemia in Patients with Breast Cancer Treated Preoperatively with Docetaxel/Doxorubicin/Cyclophosphamide. Supportive Cancer Therapy, 2006, 3, 103-109.	0.3	4
232	Neoadjuvant Clinical Trials for the Treatment of Primary Breast Cancer: The Experience of the German Study Groups. Current Oncology Reports, 2012, 14, 27-34.	1.8	4
233	Evolution of adjuvant chemotherapy for breast cancer. Lancet, The, 2015, 385, 1812-1814.	6.3	4
234	Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). European Journal of Cancer, 2021, 156, 138-148.	1.3	4

#	Article	IF	Citations
235	Response-based molecular subtypingâ€"emergence of the third generation of breast cancer subtypes. Cancer Cell, 2022, 40, 592-594.	7.7	4
236	Reply to A. Morabito et al and G. Valabrega et al. Journal of Clinical Oncology, 2009, 27, e124-e125.	0.8	3
237	What Can Be Learned From Trials Running Short of Patients or Events?. Journal of Clinical Oncology, 2012, 30, 901-903.	0.8	3
238	Present Status of Adjuvant Chemotherapy for Elderly Breast Cancer Patients. Breast Care, 2012, 7, 439-444.	0.8	3
239	Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy. Breast Care, 2018, 13, 440-446.	0.8	3
240	A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA). Anti-Cancer Drugs, 2019, 30, 394-401.	0.7	3
241	Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases â€“ a transSENTINA Analysis. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1229-1236.	0.8	3
242	Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting.. Journal of Clinical Oncology, 2018, 36, 568-568.	0.8	3
243	Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy. Journal of the National Cancer Institute, 2022, 114, 1117-1126.	3.0	3
244	Reply to L. Del Mastro and Z. Blumenfeld. Journal of Clinical Oncology, 2011, 29, 3341-3342.	0.8	2
245	Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial. Breast Care, 2011, 6, 457-461.	0.8	2
246	Targeting the Immune System in Breast Cancer: Hype or Hope?: TILs and Newer Immune-Based Therapies Being Evaluated for HER2+ and TNBC. Current Breast Cancer Reports, 2015, 7, 203-209.	0.5	2
247	Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 143-151.	1.4	2
248	Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1110-1117.	0.8	2
249	Autologous Lipotransfer - Daily Therapeutic Practice in Breast Cancer: An Intergroup Analysis Encompassing NOGGO, WSG, GBG, AWO Gyn and DGPRÃ„C. Breast Care, 2019, 14, 165-169.	0.8	2
250	Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.. Journal of Clinical Oncology, 2021, 39, 519-519.	0.8	2
251	Reply to Y. Kawamura et al. Journal of Clinical Oncology, 2021, 39, 3090-3091.	0.8	2
252	Data describing the poor outcome associated with a breast cancer diagnosis in the post-weaning period. Data in Brief, 2021, 38, 107354.	0.5	2

#	Article	IF	Citations
253	Prevention Trials in Women at Moderate Risk of Breast Cancer. Breast Care, 2006, 1, 298-303.	0.8	1
254	Reply to F. Bellati et al. Journal of Clinical Oncology, 2010, 28, e473-e473.	0.8	1
255	Opinions on the ASCO 2011 Annual Meeting. Breast Care, 2011, 6, 315-319.	0.8	1
256	Concerning Dediu M, Zielinski A: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. Breast Care 2019; Doi 10.1159/000500620. Breast Care, 2020, 15, 96-101.	0.8	1
257	Reporting the Analytical Method Is Essential to Assessing Studies in Which Biomarkers Are a Major Study Objectiveâ€"Reply. JAMA Oncology, 2021, 7, 1403.	3.4	1
258	The Dual Role of Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2â€"Positive Primary Breast Cancer. JAMA Oncology, 2015, 1, 455.	3.4	1
259	Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?. Lancet Oncology, The, 2022, 23, 325-328.	5.1	1
260	Bericht vom 5. GBG-Jahrestreffen 07.–08.03.2008. Breast Care, 2008, 3, 139-143.	0.8	0
261	Bericht vom 6. GBG-Jahrestreffen 19.–20.02.2009. Breast Care, 2009, 4, 130-134.	0.8	0
262	Can We Keep the â€˜PROMISEâ€™?. Breast Care, 2011, 6, 467-470.	0.8	0
263	News from the San Antonio Breast Cancer Symposium 2010. Breast Care, 2011, 6, 56-61.	0.8	0
264	Incorporating Agents that Target HER2 in the Neoadjuvant Setting. Current Breast Cancer Reports, 2011, 3, 190-196.	0.5	0
265	Breast Cancer in Young Women - News from the BCY3 Consensus Conference. Breast Care, 2016, 11, 432-435.	0.8	0
266	Efficacy + safety of palbociclib (P) in patients (pts) â‰¥50 y with hormone receptorâ€'positive (HR+)/human epidermal growth factor receptor 2â€'negative (HER2â€“) advanced breast cancer (ABC): subgroup analysis of 2 randomized phase 3 studies. Breast, 2018, 41, S11-S12.	0.9	0
267	Breast Cancer in Young and Premenopausal Women. Annals of Oncology, 2019, 30, vi67.	0.6	0
268	Post-Neoadjuvant Therapy. Breast Care, 2019, 14, 409-413.	0.8	0
269	A PLAIN-LANGUAGE SUMMARY OF THE SOLAR-1 TRIAL: STUDYING ALPELISIB WITH FULVESTRANT IN PATIENTS WITH HR+, HER2â€“ ADVANCED BREAST CANCER WHO HAD PREVIOUSLY RECEIVED AN AROMATASE INHIBITOR. Breast, 2019, 48, S48.	0.9	0
270	Corrigendum to â€œEfficacyÂ+ safety of palbociclib (P) in patients (pts) â‰¥50 y with hormone receptorâ€'positive (HR+)/human epidermal growth factor receptor 2â€'negative (HER2â€“) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studiesâ€•[Breast 41S1 (2018) S11â€“12]. Breast, 2020, 49, 131.	0.9	0

#	Article	IF	Citations
271	THE ALPELISIB (ALP) EXPERIENCE IN THE SOLAR-1 AND BYLIEVE STUDIES: PERSPECTIVES FOR PRACTITIONERS CARING FOR PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2â€“) ADVANCED BREAST CANCER (ABC). Breast, 2021, 59, S49.	0.9	0